Evommune (EVMN) Operating Expenses (2024 - 2026)

Evommune (EVMN) has 3 years of Operating Expenses data on file, last reported at $24.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 32.84% year-over-year to $24.0 million in Q1 2026; TTM through Mar 2026 was $95.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $94.1 million, up 22.15% from the prior year.
• Operating Expenses for Q1 2026 stood at $24.0 million, down from $29.7 million in the prior quarter.
• Over the last five years, Operating Expenses for EVMN reached as high as $29.7 million in Q4 2025 and fell as low as $16.5 million in Q3 2024.
• Historically, Operating Expenses has averaged $22.2 million across 3 years, with a median of $22.4 million in 2024.
• Across the five-year window, Operating Expenses jumped 41.24% in 2025 and surged 32.84% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $21.5 million in 2024, then jumped by 38.51% to $29.7 million in 2025, then slipped by 19.39% to $24.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $24.0 million in Q1 2026, $29.7 million in Q4 2025, and $23.3 million in Q3 2025.